Laboratoires IPRAD and BIOCODEX have entered into exclusive negotiations on the acquisition of Laboratoires IPRAD by Biocodex.
Biocodex and Laboratoires IPRAD have complementary product portfolios in the field of family health. The two companies together should make Biocodex a major player, particularly in the domain of microbiotas, with two-thirds of the overall turnover which is generated internationally.
Laboratoires IPRAD is a family business founded in 1989. It has enjoyed strong growth over the last 30 years, as a proud leader on the French Feminine Care market, mainly thanks to the Saforelle® brand. With also Mucogyne®, Gestarelle®, Physioflor® and a drug gynecologic portfolio Secnol® and Gydrelle®. IPRAD is also active in the Family Care market, with Thalamag® or Chronodorm® brands.
Biocodex is also a family business, founded in 1953, and is known for its expertise in gastroenterology, thanks to its flagship strain, Saccharomyces Boulardii CNCM i-745, launched under the brand Ultra- Levure® in France, and Enterol®, Floratil® or Bioflor® abroad. Biocodex has established itself as a leader in the field of microbiota, with the recent launch of Symbiosys®, an innovative range of probiotics, by the Biocodex Microbiota Foundation, which finances fundamental research, and by the Biocodex Microbiota Institute. Biocodex has proven expertise in the central nervous system, particularly with its development of the innovative orphan medicine, Diacomit®, an anticonvulsant indicated for Dravet syndrome.
The new dynamic that will arise from the synergy of the two companies will help consolidate the growth of both groups. It will strengthen our respective positioning in France and speed up the international development of Laboratoires IPRAD products, thanks to Biocodex’s solid foothold comprised of 17 subsidiaries and a network of about a hundred distributors.
The family that founded Laboratoires IPRAD has chosen another family group that shares the same values in the hopes of preserving the Group’s foundation and boosting growth.
Subject to the information and authorization procedures laid down by the applicable regulations, inclusing the authorization of Autorité française de la concurrence, the definitive acquisition will come into effect in January 2020.